Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Obesity Treatment” program sellers settle

This article was originally published in The Tan Sheet

Executive Summary

Xavier Rodriguez and Santa Ana, Calif.-based Centro Natural Services, sellers of Centro Natural de Salud Obesity Treatment, settled with the Federal Trade Commission on a charge they made false and unsubstantiated claims their product leads to fast, substantial and permanent weight loss without dieting, FTC says Jan. 30. The settlement includes a judgment of nearly $2.4 million, but all but $20,000 is suspended because of the defendants' inability to pay. The settlement bans the defendants from representing a weight-loss product will lead to rapid weight loss without reducing caloric intake, or will cause users to "lose as much as a half-pound per day for multiple weeks and months," or "lose weight permanently"...

You may also be interested in...



US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.

Colgate Was Drawn To Hello Products’ Youthful Lifestyle Branding, And Now It Has A CBD Line

Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Topics

UsernamePublicRestriction

Register

PS101329

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel